Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 1; referees: 2 approved]
While double-blinding is a crucial aspect of study design in an interventional clinical trial of medication for a disorder with subjective endpoints such as major depressive disorder, psychotherapy clinical trials, particularly cognitive-behavioral therapy trials, cannot be double-blinded. This pape...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
F1000 Research Ltd
2015-08-01
|
| Series: | F1000Research |
| Subjects: | |
| Online Access: | http://f1000research.com/articles/4-638/v1 |
| _version_ | 1818341631307284480 |
|---|---|
| author | Douglas Berger |
| author_facet | Douglas Berger |
| author_sort | Douglas Berger |
| collection | DOAJ |
| description | While double-blinding is a crucial aspect of study design in an interventional clinical trial of medication for a disorder with subjective endpoints such as major depressive disorder, psychotherapy clinical trials, particularly cognitive-behavioral therapy trials, cannot be double-blinded. This paper highlights the evidence-based medicine problem of double-blinding in the outcome research of a psychotherapy and opines that psychotherapy clinical trials should be called, “partially-controlled clinical data” because they are not double-blinded. The implications for practice are, 1. For practitioners to be clear with patients the level of rigor to which interventions have been studied, 2. For authors of psychotherapy outcome studies to be clear that the problem in the inability to blind a psychotherapy trial severely restricts the validity of any conclusions that can be drawn, and 3. To petition National Health Insurance plans to use caution in approving interventions studied without double-blinded confirmatory trials as they may lead patients to avoid other treatments shown to be effective in double-blinded trials. |
| first_indexed | 2024-12-13T16:01:52Z |
| format | Article |
| id | doaj.art-0e36c73944da4eedbfae486592d3ef2e |
| institution | Directory Open Access Journal |
| issn | 2046-1402 |
| language | English |
| last_indexed | 2024-12-13T16:01:52Z |
| publishDate | 2015-08-01 |
| publisher | F1000 Research Ltd |
| record_format | Article |
| series | F1000Research |
| spelling | doaj.art-0e36c73944da4eedbfae486592d3ef2e2022-12-21T23:39:08ZengF1000 Research LtdF1000Research2046-14022015-08-01410.12688/f1000research.6953.17488Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 1; referees: 2 approved]Douglas Berger0Meguro Counseling Center, Tokyo, JapanWhile double-blinding is a crucial aspect of study design in an interventional clinical trial of medication for a disorder with subjective endpoints such as major depressive disorder, psychotherapy clinical trials, particularly cognitive-behavioral therapy trials, cannot be double-blinded. This paper highlights the evidence-based medicine problem of double-blinding in the outcome research of a psychotherapy and opines that psychotherapy clinical trials should be called, “partially-controlled clinical data” because they are not double-blinded. The implications for practice are, 1. For practitioners to be clear with patients the level of rigor to which interventions have been studied, 2. For authors of psychotherapy outcome studies to be clear that the problem in the inability to blind a psychotherapy trial severely restricts the validity of any conclusions that can be drawn, and 3. To petition National Health Insurance plans to use caution in approving interventions studied without double-blinded confirmatory trials as they may lead patients to avoid other treatments shown to be effective in double-blinded trials.http://f1000research.com/articles/4-638/v1Drug Discovery & DesignMood DisordersNeuropharmacology & PsychopharmacologyScience & Medical Policies |
| spellingShingle | Douglas Berger Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 1; referees: 2 approved] F1000Research Drug Discovery & Design Mood Disorders Neuropharmacology & Psychopharmacology Science & Medical Policies |
| title | Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 1; referees: 2 approved] |
| title_full | Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 1; referees: 2 approved] |
| title_fullStr | Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 1; referees: 2 approved] |
| title_full_unstemmed | Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 1; referees: 2 approved] |
| title_short | Double-Blinding and Bias in Medication and Cognitive-Behavioral Therapy Trials for Major Depressive Disorder [version 1; referees: 2 approved] |
| title_sort | double blinding and bias in medication and cognitive behavioral therapy trials for major depressive disorder version 1 referees 2 approved |
| topic | Drug Discovery & Design Mood Disorders Neuropharmacology & Psychopharmacology Science & Medical Policies |
| url | http://f1000research.com/articles/4-638/v1 |
| work_keys_str_mv | AT douglasberger doubleblindingandbiasinmedicationandcognitivebehavioraltherapytrialsformajordepressivedisorderversion1referees2approved |